Pharma lobbyists focus on a surprising new target: the FDA - STAT
Pharmaceutical lobbyists see opportunities to influence FDA decisions under the Trump administration, believing that approvals are more likely if they can be framed as wins for the administration. Despite promises from Health Secretary Robert F. Kennedy Jr. to reduce industry influence, the current political environment has increased industry efforts to engage with the FDA, changing the nature of these interactions.
WASHINGTON — Health secretary Robert F. Kennedy Jr. has repeatedly promised to root out industry influence from the Food and Drug Administration.
But the Trump administration’s injection of political priorities into the agency, which has long been shielded from such meddling, has opened new avenues for lobbying. The pharmaceutical industry is working to capitalize, according to 10 people, including lobbyists, advisers, FDA officials, and an executive involved in the efforts.
“The nature of the relationship is so drastically different now,” Michael Abrams, a managing partner at Numerof and Associates who works with pharmaceutical clients on regulatory requirements, said of the interactions between companies and the administration. Abrams said the new system, under Trump, makes discussions about FDA decisions that once would have been “heretical” the new norm.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Comments (0)
No comments yet. Be the first to share your thoughts.
Sign in to leave a comment.